• Publications
  • Influence
Mutational landscape and clonal architecture in grade II and III gliomas
Grade II and III gliomas are generally slowly progressing brain cancers, many of which eventually transform into more aggressive tumors. Despite recent findings of frequent mutations in IDH1 andExpand
  • 479
  • 23
Current Trends in Targeted Therapies for Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is one of the most frequently occurring tumors in the central nervous system and the most malignant tumor among gliomas. Despite aggressive treatment including surgery,Expand
  • 116
  • 7
  • PDF
Novel somatic and germline mutations in intracranial germ cell tumours
Intracranial germ cell tumours (IGCTs) are a group of rare heterogeneous brain tumours that are clinically and histologically similar to the more common gonadal GCTs. IGCTs show great variation inExpand
  • 117
  • 6
  • PDF
EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.
Gefitinib--a specific inhibitor of epidermal growth factor receptor (EGFR)-associated tyrosine kinase--has demonstrated efficacy in a subgroup of patients with non-small-cell lung carcinoma (NSCLC)Expand
  • 87
  • 6
Benefits of interferon‐β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter
The aim of the current study was to catalog genomic and epigenomic abnormalities in newly diagnosed glioblastoma patients and determine the correlation among clinical, genetic, and epigeneticExpand
  • 84
  • 6
IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.
Alkylating agents, such as temozolomide, are among the most effective cytotoxic agents used for malignant gliomas, but responses remain very poor. The DNA repair protein O6-methylguanine-DNAExpand
  • 97
  • 5
  • PDF
Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas.
Hepatocellular carcinoma (HCC) most commonly arises from chronic inflammation due to viral infection, as a result of genetic and epigenetic abnormalities. A global picture of epigenetic changes inExpand
  • 120
  • 4
  • PDF
The DNA demethylating agent 5‐aza‐2′‐deoxycytidine activates NY‐ESO‐1 antigenicity in orthotopic human glioma
Cancer/testis antigens (CTAs) are considered to be suitable targets for the immunotherapy of human malignancies. It has been demonstrated that in a variety of tumors, the expression of certain CTAsExpand
  • 79
  • 4
The Modulation of MicroRNAs by Type I IFN through the Activation of Signal Transducers and Activators of Transcription 3 in Human Glioma
Type I IFNs are involved in double-stranded RNA responses. Here, we investigated the possibility that IFN-β may induce or downregulate cellular microRNAs (miRNA) in human neoplasms and thereby useExpand
  • 49
  • 4
  • PDF
Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment
Targeting self-renewal is an important goal in cancer therapy and recent studies have focused on Notch signalling in the maintenance of stemness of glioma stem cells (GSCs). UnderstandingExpand
  • 137
  • 3